Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivocizumab + docetaxel + cisplatin induction in locally advanced head and neck squamous cell carcinoma
ChiCTR2500107060Phase 2Not yet recruiting
- Sponsor
- Sichuan Cancer Hospital
- Start
- Aug 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ivonescimab in head and neck squamous cell carcinoma (HNSCC), sponsored by Sichuan Cancer Hospital. Primary endpoint: Objective response rate (ORR). Planned start Aug 2025; status: not yet recruiting.
02
Drugs
ivonescimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on ChiCTR2500107060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500107060.